No Data
Nuotai Biotechnology (688076.SH): The Active Pharmaceutical Ingredient of Incevik has obtained the FDA DMF registration number.
On April 17, Gelonghui reported that Nuotai Biomedical (688076.SH) announced that its holding subsidiary, Hangzhou Nuotai Nuohe Biomedical Technology Co., Ltd., received a DMF receipt from the USA Food and Drug Administration (referred to as "FDA") regarding the Active Pharmaceutical Ingredient (API) of Inclisiran, and the company's Active Pharmaceutical Ingredient has successfully obtained the DMF filing number. Inclisiran is a long-acting lipid-lowering drug based on siRNA that can degrade the messenger RNA (mRNA) of PCSK9 in the liver, blocking the synthesis of PCSK9 protein, thus reducing the circulating LDL-C levels. It was initially introduced in December 2021.
We Ran A Stock Scan For Earnings Growth And Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Passed With Ease
NuoTai Bio (688076.SH): An agreement has been reached with Julphar regarding the supply of the active pharmaceutical ingredient Semaglutide.
On April 9, Gelonghui reported that Novartis Bio (688076.SH) announced a strategic partnership with the well-known Middle Eastern pharmaceutical company Gulf Pharmaceutical Industries (Julphar PSC) (referred to as "Julphar"). The company will reach related agreements with Julphar on the supply of the Active Pharmaceutical Ingredient Semaglutide in 22 countries in the Middle East and Africa, including the UAE, Qatar, Saudi Arabia, Egypt, and Morocco.
Nuotai Biotechnology (688076.SH): Currently, there are no related deployments in the field of Innovative Drugs.
On April 7, Gelonghui reported that Nuotai Biological (688076.SH) stated on the interactive platform that the company currently has no relevant layout in Innovative Drugs.
Sinopep-Allsino Biopharmaceutical's Lianyungang Facility Passes GMP Inspection
Jiangsu Sinopep-Allsino Biopharmaceutical Gets EU Export Nod for Type 2 Diabetes Drug API
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%
